Fuhonghanlin (02696): Hanshuang (Sutrilumab Injection) combined with chemotherapy for neoadjuvant/adjuvant therapy for gastric cancer officially included in the National Medical Products Administration Drug Evaluation Center's groundbreaking therapy program.

Wisdom Financial News APP News, Fosun Pharma (02696) announced that recently, Hansrucin (Suliri monoclonal antibody injection) combined with chemotherapy neoadjuvant/adjuvant therapy for gastric cancer has been officially included in the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE)'s breakthrough therapy program.